Regeneron Pharmaceuticals, Inc. vs Arrowhead Pharmaceuticals, Inc.: A Gross Profit Performance Breakdown

Biotech Giants: A Decade of Gross Profit Growth

__timestampArrowhead Pharmaceuticals, Inc.Regeneron Pharmaceuticals, Inc.
Wednesday, January 1, 20141750002614539000
Thursday, January 1, 20153820003711019000
Friday, January 1, 20161583334560733000
Sunday, January 1, 2017314077095475166000
Monday, January 1, 2018161423216276700000
Tuesday, January 1, 20191687955777081200000
Wednesday, January 1, 2020879920667377200000
Friday, January 1, 202113828700013634200000
Saturday, January 1, 202223281000010612500000
Sunday, January 1, 202324073500011301400000
Monday, January 1, 2024355100012231500000
Loading chart...

Infusing magic into the data realm

A Tale of Two Biotechs: Gross Profit Trends from 2014 to 2023

In the competitive world of biotechnology, Regeneron Pharmaceuticals, Inc. and Arrowhead Pharmaceuticals, Inc. have showcased contrasting trajectories in gross profit over the past decade. Regeneron, a leader in the industry, has consistently demonstrated robust growth, with its gross profit peaking at approximately $13.6 billion in 2021, marking a staggering 420% increase from 2014. In contrast, Arrowhead Pharmaceuticals, while showing significant growth, remains a smaller player. Its gross profit surged from a modest $175,000 in 2014 to over $240 million in 2023, reflecting a remarkable 137,000% increase. However, the data for 2024 is incomplete, leaving room for speculation on future trends. This analysis highlights the dynamic nature of the biotech sector, where innovation and strategic investments can lead to exponential growth, as seen in these two companies' financial journeys.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025